You are here

Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May

Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May

Submitted by CP Staff on June 8, 2018 - 11:59pm

Source:

Motley Fool

News Tags:

Editas Medicine

Intellia Therapeutics

CRISPR Therapeutics

Headline:

Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May

snippet:

t was a great month for shareholders holding any piece of the fledgling field of CRISPR gene editing technologies. Shares of Editas Medicine (NASDAQ:EDIT) rose over 22%, Intellia Therapeutics (NASDAQ:NTLA) gained 33.4%, and CRISPR Therapeutics (NASDAQ:CRSP)jumped an impressive 47.1%, according to data provided by S&P Global Market Intelligence.